DE706657T1 - Wechselwirkungen von inhibierungsproteinen - Google Patents

Wechselwirkungen von inhibierungsproteinen

Info

Publication number
DE706657T1
DE706657T1 DE0706657T DE94920178T DE706657T1 DE 706657 T1 DE706657 T1 DE 706657T1 DE 0706657 T DE0706657 T DE 0706657T DE 94920178 T DE94920178 T DE 94920178T DE 706657 T1 DE706657 T1 DE 706657T1
Authority
DE
Germany
Prior art keywords
interactions
inhibition proteins
inhibition
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0706657T
Other languages
English (en)
Inventor
Joseph Avruch
Xian-Feng Zhang
Mark Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Indiana University Foundation
Original Assignee
General Hospital Corp
Indiana University Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Indiana University Foundation filed Critical General Hospital Corp
Publication of DE706657T1 publication Critical patent/DE706657T1/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
DE0706657T 1993-06-11 1994-06-10 Wechselwirkungen von inhibierungsproteinen Pending DE706657T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/077,256 US5582995A (en) 1993-06-11 1993-06-11 Methods of screening for compounds which inhibit the direct binding of Ras to Raf
PCT/US1994/006654 WO1994029727A1 (en) 1993-06-11 1994-06-10 Inhibiting protein interactions

Publications (1)

Publication Number Publication Date
DE706657T1 true DE706657T1 (de) 2003-05-28

Family

ID=22137014

Family Applications (1)

Application Number Title Priority Date Filing Date
DE0706657T Pending DE706657T1 (de) 1993-06-11 1994-06-10 Wechselwirkungen von inhibierungsproteinen

Country Status (6)

Country Link
US (4) US5582995A (de)
EP (1) EP0706657A4 (de)
JP (1) JPH09504860A (de)
CA (1) CA2163905A1 (de)
DE (1) DE706657T1 (de)
WO (1) WO1994029727A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US6770446B1 (en) 1994-06-14 2004-08-03 Wyeth Cell systems having specific interaction of peptide binding pairs
US5989808A (en) * 1994-06-14 1999-11-23 American Cyanamid Company Identification of compounds affecting specific interaction of peptide binding pairs
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5597719A (en) * 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
US6107457A (en) 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6103692A (en) * 1996-03-12 2000-08-15 The General Hospital Corporation Inhibiting protein interactions
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6235538B1 (en) * 1997-03-05 2001-05-22 The Board Of Regents Of The University Of Oklahoma Test for detecting substances which alter the conformational structure of zinc fingers
US5885783A (en) * 1997-07-02 1999-03-23 Yoo; Tai-June Autoimmune inner ear disease antigen and diagnostic assay
DK1017384T3 (da) 1997-09-26 2005-01-31 Zentaris Gmbh Azabenzimidazolbaserede forbindelser til modulation af serin/threoninproteinkinasefunktion
AU1094699A (en) 1997-10-15 1999-05-03 Diversa Corporation Screening for novel compounds which regulate biological interactions
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6156526A (en) * 1998-07-21 2000-12-05 The Rockerfeller University Crystal of a Ras-Sos complex and methods of use thereof
IL141104A0 (en) * 1998-07-27 2002-02-10 Webtv Networks Inc Remote computer access
US6995249B1 (en) * 1998-08-14 2006-02-07 Japan Science And Technology Corporation Nucleic acid capable of binding specifically to Ras target protein
CA2347653A1 (en) * 1998-10-13 2000-04-20 Onyx Pharmaceuticals, Inc. Novel cell signaling polypeptides and nucleic acids
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7166475B2 (en) * 1999-02-26 2007-01-23 Cyclacel Ltd. Compositions and methods for monitoring the modification state of a pair of polypeptides
US6177523B1 (en) 1999-07-14 2001-01-23 Cardiotech International, Inc. Functionalized polyurethanes
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
AU5077401A (en) * 2000-02-08 2001-08-20 Sangamo Biosciences Inc Cells for drug discovery
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US20020150566A1 (en) * 2001-03-23 2002-10-17 Kun-Liang Guan Method of inhibiting cancerous cell proliferation using Ras mutants of GDP-bound conformation
PT2332582E (pt) 2002-06-19 2014-01-28 Apeiron Biologics Ag Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
US7923209B2 (en) * 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
EP1797427A4 (de) * 2004-09-22 2009-04-08 Odyssey Thera Inc Verfahren zur identifizierung neuer arzneimittel-leads und neuer therapeutischer verwendungen für bekannte arzneimittel
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
EP3016972A2 (de) * 2013-07-03 2016-05-11 Université Pierre et Marie Curie (Paris 6) Pro-apoptotische ras- und raf-peptide
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
US20220307013A1 (en) * 2019-08-30 2022-09-29 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
CA1335431C (en) * 1988-05-31 1995-05-02 Yoshimi Takai Gtp binding protein and method for production thereof
FR2633639B1 (fr) * 1988-07-04 1991-05-10 Inst Nat Sante Rech Med Nouvelles sequences d'acides amines, acides nucleiques codant pour ces sequences d'acides amines et leurs applications, notamment pour le diagnostic, in vitro, de pathologies liees a l'action de facteurs oncogenes
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
EP0496162A3 (en) * 1990-12-24 1993-09-01 Merck & Co. Inc. Peptide inhibitors of ras-gap interaction
AU2552492A (en) * 1991-08-23 1993-03-16 United States of America as represented by The Secretary Department of Health and Human Services, The Raf protein kinase therapeutics
WO1993006248A1 (en) * 1991-09-16 1993-04-01 The United States Of America Represented By The Secretary, Department Of Health & Human Services Detection method for c-raf-1 genes
US5597719A (en) * 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins

Also Published As

Publication number Publication date
WO1994029727A1 (en) 1994-12-22
US5763571A (en) 1998-06-09
US5767075A (en) 1998-06-16
EP0706657A1 (de) 1996-04-17
US5582995A (en) 1996-12-10
US5736337A (en) 1998-04-07
EP0706657A4 (de) 2002-10-24
JPH09504860A (ja) 1997-05-13
CA2163905A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
DE706657T1 (de) Wechselwirkungen von inhibierungsproteinen
DE69434520D1 (de) Biotinylierung von proteinen
DE69431458D1 (de) Echtheitsüberprüfung von Gegenständen
DE69418220D1 (de) Befestigung von Biomolekülen
DK91192D0 (da) Protein
DE69634998D1 (de) Kontrolle von Kanten
DE69509714T2 (de) Zerstörung von Unterwasser-Gegenständen
DE69220382D1 (de) Verwendung von Peptidderivaten
DE69626729D1 (de) Kombination von Datenwerten
FI960253A0 (fi) Aerosolisoitujen proteiinien stabilointi
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DK132892D0 (da) Proteiner
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE69401956T2 (de) Verbesserungen von seifenstücken
DE69404303T2 (de) Verbesserungen von seifenstücken
ATA136995A (de) Abreicherung von 7-adca in 3-vinyl-aca
DK75393D0 (da) Production of protein
DE68904315T2 (de) Peptide-hemmer von phospholipase a2.
DE69331549D1 (de) Nachweiss von anti-hpa antikörpern
DE69418676D1 (de) Deprotonierung von Cyclopentadienylderivate
DE29509987U1 (de) Bausatz von Steckverbindern
DE9309721U1 (de) Verbindung von Gegenständen
DE69404145T2 (de) Zusammensetzungen von stoffen
DK36193D0 (da) Fremgangsmaade
DE69417915D1 (de) Reinigung von uranhexafluorid